LOUIS D. LIETO
Dr. Louis D. Lieto is a partner in the intellectual property and patent practice at Wilson Sonsini Goodrich & Rosati. Lou focuses on patent prosecution, strategic patent counseling, and IP due diligence in a variety of fields, including biofuels, immunotherapeutics, medical devices, pharmaceuticals, stem cells, and transgenic animals.
Lou received his Ph.D. from the University of Kentucky, where he focused on characterizing the molecular and genetic basis of hereditary disease. Subsequently, Lou completed his postdoctoral fellowship in immunology at the National Institute of Allergy and Infectious Diseases (NIAID). At NIAID, Lou conducted research in the fields of immunology and molecular biology to examine the regulation of gene expression of human immuno-regulatory receptors.
Prior to joining Wilson Sonsini Goodrich & Rosati, Lou was a patent examiner at the U.S. Patent and Trademark Office, where he examined applications for inventions encompassing several fields, including proteins, DNA vectors, nucleic acid vaccines, immune cell therapy, stem cell therapy, transgenic animals, and gene therapy.EDUCATION:
- J.D., George Washington University Law School
- Ph.D., Veterinary Science, University of Kentucky
Authored dissertation titled "The Genetic Basis of Epitheliogenesis Imperfecta in Equus caballus"
- B.S., Ecology and Evolutionary Biology, University of Rochester
Minor in Political Science
- American Academy of Allergy, Asthma and Immunology
- American Association of Immunologists
- American Intellectual Property Law Association
- International Society for Animal Genetics
- Co-author, "The Serious and Immense Impact of a Medical Device Hack," Law360, January 12, 2017
- Co-author, Brief for amici curiae Amarantus Bioscience Holdings, Inc., Exo Incubator, Inc., and Michael Heltzen in support of petitioner, Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al., On Petition for a Writ of Certiorari to the U.S. Supreme Court, No. 15-1182
- Co-author, Brief for amici curiae Population Diagnostics, Inc., Avant Diagnostics, Inc., Personalis, Inc., Linda Bruzzone, and Erin Marie Mading in support of petitioner, Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al., On Petition for a Writ of Certiorari to the U.S. Supreme Court, No. 15-1182
- Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
- Co-author with D.M. Hoffmeister, V. Norviel, T.J. Noh, M.C. Easterday, P. Girinath, and C. Andres, "Reflections on the Remarkable Rise of Orphan Drugs," Law360, January 28, 2015
- Co-author with C. Andres, V. Norviel, E. Kepplinger, J. Chambers, and C. McAndrew, "Strategies for Maximizing Patent Claim Scope and Patent Protection for Diagnostic Method Claims in the Wake of Mayo v. Prometheus," The Life Sciences Report, Wilson Sonsini Goodrich & Rosati, Spring 2013
- Co-author with V. Norviel, "Fast or Slow? Strategies to Speed Up the Patent Process Among Worldwide Patent Offices," The Intellectual Property Strategist, Vol. 17, No. 4, January 2011
- Co-author with F. Borrego, K. Maasho, D. West, and J.E. Coligan, "The Human CD94 Gene Codes for Multiple, Expressible Transcripts including a New Partner of NKG2A/B," 7 Genes and Immunity 36-43, 2006
- Co-author with F. Borrego and J.E. Coligan, "CD94 1A/1B: A Window Opens into NK Cell Development," 106 Blood 3338-9, 2005
- Co-author with A.I. Marusina, D.K. Kim, F. Borrego, and J.E. Coligan, "GATA-3 Is an Important Transcription Factor for Regulating Human NKG2A Gene Expression," 174 Journal of Immunology 2152-9, 2005
- Co-author with T.W. Swerczek and E.G. Cothran, "Developmental Defects of Enamel in American Saddlebred Foals with Epitheliogenesis Imperfecta," 24 Journal of Equine Veterinary Science 1-5, 2004
- Please see wsgr.com for a complete list of publications.
- Bar of the District of Columbia
- State Bar of Massachusetts
- State Bar of New Hampshire
- U.S. District Court for the District of New Hampshire
- U.S. Patent and Trademark Office